This study aimed to explore the function of Seleno-chitooligosaccharide (SOA) on the intestinal barrier through regulation of inflammatory cytokines, tight junction protein, and gut microbiota in mice. The results of ELISA assay demonstrated that SOA significantly increased the levels of IL-2, IL-10, and IFN-γ in serum and ileum. Meanwhile, SOA increased the levels of IL-4 in the ileum (p < 0.05). In addition, Diamine Oxidase (DAO) concentration was decreased in ileum by SOA treatments (p < 0.05). The administration of SOA significantly upregulated the expression of ZO-1 and Occludin in the ileum (p < 0.05). By 16S rDNA sequencing, reduced ratio of Bacillota/Bacteroidota was observed in SOA treated mice. Within the phylum of Bacteroidota, SOA increased the relative abundance of Deferribacterota, uncultured Bacteroidales bacterium, and Bacteroides. Within the phylum of Bacillota, increased relative abundance of Erysipelatoclostridium and Lachnoclostridium, and reduced relative abundance of Ruminococcaceae UCG-010 were observed with SOA supplement. In summary, SOA has the potential to modulate the function of intestinal barrier function and prevent intestinal diseases.
- MeSH
- Chitin pharmacology analogs & derivatives metabolism MeSH
- Chitosan MeSH
- Cytokines * metabolism MeSH
- Intestinal Barrier Function MeSH
- Ileum microbiology drug effects metabolism MeSH
- Mice MeSH
- Oligosaccharides * pharmacology metabolism MeSH
- Tight Junction Proteins * metabolism genetics MeSH
- Gastrointestinal Microbiome * drug effects MeSH
- Intestinal Mucosa * metabolism drug effects microbiology MeSH
- Animals MeSH
- Check Tag
- Male MeSH
- Mice MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
Histaminová intolerance (HI, HIT) může být označena rovněž jako enterální histaminóza nebo jako hypersenzitivita na orální/potravinový histamin. Jde o neschopnost degradace exogenního histaminu z důvodu zhoršené aktivity diaminooxidázy (DAO), což vede k příznakům z histaminového nadbytku. HI bychom měli chápat jen jako variabilní soubor příznaků, nejde ani o nozologickou jednotku, ani o syndrom. O diagnostice této metabolické poruchy rozhodují výhradně klinická kritéria spolu s prokazatelným efektem nízkohistaminové diety. Biomarkery nemají pro HI dostatečnou specificitu ani senzitivitu. Funkční i absolutní deficit DAO může být způsoben faktory genetickými, farmakologickými, anebo širokou heterogenní skupinou primárních enteropatií (sekundární HI).
Histamine intolerance (HI, HIT) may also be referred to as enteral histaminosis or hypersensitivity to oral/food histamine. It is the inability to degrade exogenous histamine due to impaired diaminooxidase (DAO) activity, resulting in symptoms of histamine excess. HI should be understood as a variable set of symptoms, neither a nosological entity nor a syndrome. The diagnosis of this metabolic disorder is made solely on the basis of clinical criteria and the demonstrated effect of a low histamine diet. No biomarkers are available for HI specificity. Both functional and absolute DAO deficiency can be caused by genetic, pharmacological or a broad heterogeneous group of primary enteropathies (secondary HI).
Histaminová intolerance (HI, HIT) může být označena rovněž jako enterální histaminóza nebo jako hypersenzitivita na orální/potravinový histamin. Jde o neschopnost degradace exogenního histaminu z důvodu zhoršené aktivity diaminooxidázy (DAO), což vede k příznakům z histaminového nadbytku. HI bychom měli chápat jen jako variabilní soubor příznaků, nejde ani o nozologickou jednotku, ani o syndrom. O diagnostice této metabolické poruchy rozhodují výhradně klinická kritéria spolu s prokazatelným efektem nízkohistaminové diety. Biomarkery nemají pro HI dostatečnou specificitu ani senzitivitu. Funkční i absolutní deficit DAO může být způsoben faktory genetickými, farmakologickými, anebo širokou heterogenní skupinou primárních enteropatií (sekundární HI).
Histamine intolerance (HI, HIT) may also be referred to as enteral histaminosis or hypersensitivity to oral/food histamine. It is the inability to degrade exogenous histamine due to impaired diaminooxidase (DAO) activity, resulting in symptoms of histamine excess. HI should be understood as a variable set of symptoms, neither a nosological entity nor a syndrome. The diagnosis of this metabolic disorder is made solely on the basis of clinical criteria and the demonstrated effect of a low histamine diet. No biomarkers are available for HI specificity. Both functional and absolute DAO deficiency can be caused by genetic, pharmacological or a broad heterogeneous group of primary enteropathies (secondary HI).
- Keywords
- histaminová intolerance,
- MeSH
- Histamine Agonists therapeutic use MeSH
- Diet Therapy MeSH
- Histamine * genetics metabolism adverse effects MeSH
- Humans MeSH
- Food Intolerance diagnosis MeSH
- Check Tag
- Humans MeSH
- Publication type
- Review MeSH
Age-related sarcopenia, resulting from a gradual loss in skeletal muscle mass and strength, is pivotal to the increased prevalence of functional limitation among the older adult community. The purpose of this meta-analysis of individual patient data is to investigate the difference in health-related quality of life between sarcopenic individuals and those without the condition using the Sarcopenia Quality of Life (SarQoL) questionnaire. A protocol was published on PROSPERO. Multiple databases and the grey literature were searched until March 2023 for studies reporting quality of life assessed with the SarQoL for patients with and without sarcopenia. Two researchers conducted the systematic review independently. A two-stage meta-analysis was performed. First, crude (mean difference) and adjusted (beta coefficient) effect sizes were calculated within each database; then, a random effect meta-analysis was applied to pool them. Heterogeneity was measured using the Q-test and I2 value. Subgroup analyses were performed to investigate the source of potential heterogeneity. The strength of evidence of this association was assessed using GRADE. From the 413 studies identified, 32 were eventually included, of which 10 were unpublished data studies. Sarcopenic participants displayed significantly reduced health-related quality of life compared with non-sarcopenic individuals (mean difference = -12.32; 95 % CI = [-15.27; -9.37]). The model revealed significant heterogeneity. Subgroup analyses revealed a substantial impact of regions, clinical settings, and diagnostic criteria on the difference in health-related quality of life between sarcopenic and non-sarcopenic individuals. The level of evidence was moderate. This meta-analysis of individual patient data suggested that sarcopenia is associated with lower health-related quality of life measured with SarQoL.
- MeSH
- Quality of Life MeSH
- Humans MeSH
- Prevalence MeSH
- Surveys and Questionnaires MeSH
- Sarcopenia * epidemiology MeSH
- Aged MeSH
- Check Tag
- Humans MeSH
- Aged MeSH
- Publication type
- Journal Article MeSH
- Meta-Analysis MeSH
- Review MeSH
BACKGROUND: Evaluating the prognosis of patients with aneurysmal subarachnoid hemorrhage (aSAH) who may be at risk of poor outcomes using grading systems is one way to make a better decision on treatment for these patients. This study aimed to compare the accuracy of the modified World Federation of Neurosurgical Societies (WFNS), WFNS, and Hunt and Hess (H&H) Grading Scales in predicting the outcomes of patients with aSAH. METHODS: From August 2019 to June 2021, we conducted a multicenter prospective cohort study on adult patients with aSAH in three central hospitals in Hanoi, Vietnam. The primary outcome was the 90-day poor outcome, measured by a score of 4 (moderately severe disability) to 6 (death) on the modified Rankin Scale (mRS). We calculated the areas under the receiver operator characteristic (ROC) curve (AUROCs) to determine how well the grading scales could predict patient prognosis upon admission. We also used ROC curve analysis to find the best cut-off value for each scale. We compared AUROCs using Z-statistics and compared 90-day mean mRS scores among intergrades using the pairwise multiple-comparison test. Finally, we used logistic regression to identify factors associated with the 90-day poor outcome. RESULTS: Of 415 patients, 32% had a 90-day poor outcome. The modified WFNS (AUROC: 0.839 [95% confidence interval, CI: 0.795-0.883]; cut-off value≥2.50; PAUROC<0.001), WFNS (AUROC: 0.837 [95% CI: 0.793-0.881]; cut-off value≥3.5; PAUROC<0.001), and H&H scales (AUROC: 0.836 [95% CI: 0.791-0.881]; cut-off value≥3.5; PAUROC<0.001) were all good at predicting patient prognosis on day 90th after ictus. However, there were no significant differences between the AUROCs of these scales. Only grades IV and V of the modified WFNS (3.75 [standard deviation, SD: 2.46] vs 5.24 [SD: 1.68], p = 0.026, respectively), WFNS (3.75 [SD: 2.46] vs 5.24 [SD: 1.68], p = 0.026, respectively), and H&H scales (2.96 [SD: 2.60] vs 4.97 [SD: 1.87], p<0.001, respectively) showed a significant difference in the 90-day mean mRS scores. In multivariable models, with the same set of confounding variables, the modified WFNS grade of III to V (adjusted odds ratio, AOR: 9.090; 95% CI: 3.494-23.648; P<0.001) was more strongly associated with the increased risk of the 90-day poor outcome compared to the WFNS grade of IV to V (AOR: 6.383; 95% CI: 2.661-15.310; P<0.001) or the H&H grade of IV to V (AOR: 6.146; 95% CI: 2.584-14.620; P<0.001). CONCLUSIONS: In this study, the modified WFNS, WFNS, and H&H scales all had good discriminatory abilities for the prognosis of patients with aSAH. Because of the better effect size in predicting poor outcomes, the modified WFNS scale seems preferable to the WFNS and H&H scales.
- MeSH
- Adult MeSH
- Hospitalization MeSH
- Humans MeSH
- Hospitals MeSH
- Odds Ratio MeSH
- Prospective Studies MeSH
- Subarachnoid Hemorrhage * diagnosis MeSH
- Check Tag
- Adult MeSH
- Humans MeSH
- Publication type
- Journal Article MeSH
- Multicenter Study MeSH
This multicentre prospective cohort study aimed to compare the accuracy of the PAASH, WFNS, and Hunt and Hess (H&H) scales in predicting the outcomes of adult patients with aneurysmal SAH presented to three central hospitals in Hanoi, Vietnam, from August 2019 to June 2021. Of 415 eligible patients, 32.0% had a 90-day poor outcome, defined as an mRS score of 4 (moderately severe disability) to 6 (death). The PAASH, WFNS and H&H scales all have good discriminatory abilities for predicting the 90-day poor outcome. There were significant differences in the 90-day mean mRS scores between grades I and II (p = 0.001) and grades II and III (p = 0.001) of the PAASH scale, between grades IV and V (p = 0.026) of the WFNS scale, and between grades IV and V (p < 0.001) of the H&H scale. In contrast to a WFNS grade of IV-V and an H&H grade of IV-V, a PAASH grade of III-V was an independent predictor of the 90-day poor outcome. Because of the more clearly significant difference between the outcomes of the adjacent grades and the more strong effect size for predicting poor outcomes, the PAASH scale was preferable to the WFNS and H&H scales.
- MeSH
- Adult MeSH
- Humans MeSH
- Patients MeSH
- Prognosis MeSH
- Prospective Studies MeSH
- Retrospective Studies MeSH
- Subarachnoid Hemorrhage * diagnosis MeSH
- Treatment Outcome MeSH
- Check Tag
- Adult MeSH
- Humans MeSH
- Publication type
- Journal Article MeSH
- Multicenter Study MeSH
OBJECTIVES: To investigate the impact of intracerebral haematoma (ICH) on the outcomes and the factors related to an ICH in patients with aneurysmal subarachnoid haemorrhage (aSAH) in a low- and middle-income country. DESIGN: A multicentre prospective cohort study. SETTING: Three central hospitals in Hanoi, Vietnam. PARTICIPANTS: This study included all patients (≥18 years) presenting with aSAH to the three central hospitals within 4 days of ictus, from August 2019 to June 2021, and excluded patients for whom the admission Glasgow Coma Scale was unable to be scored or patients who became lost at 90 days of follow-up during the study. OUTCOME MEASURES: The primary outcome was ICH after aneurysm rupture, defined as ICH detected on an admission head CT scan. The secondary outcomes were 90-day poor outcomes and 90-day death. RESULTS: Of 415 patients, 217 (52.3%) were females, and the median age was 57.0 years (IQR: 48.0-67.0). ICH was present in 20.5% (85/415) of patients with aSAH. There was a significant difference in the 90-day poor outcomes (43.5% (37/85) and 29.1% (96/330); p=0.011) and 90-day mortality (36.5% (31/85) and 20.0% (66/330); p=0.001) between patients who had ICH and patients who did not have ICH. The multivariable regression analysis showed that systolic blood pressure (SBP) ≥140 mm Hg (adjusted odds ratio (AOR): 2.674; 95% CI: 1.372 to 5.214; p=0.004), World Federation of Neurosurgical Societies (WFNS) grades II (AOR: 3.683; 95% CI: 1.250 to 10.858; p=0.018) to V (AOR: 6.912; 95% CI: 2.553 to 18.709; p<0.001) and a ruptured middle cerebral artery (MCA) aneurysm (AOR: 3.717; 95% CI: 1.848 to 7.477; p<0.001) were independently associated with ICH on admission. CONCLUSIONS: In this study, ICH was present in a substantial proportion of patients with aSAH and contributed significantly to a high rate of poor outcomes and death. Higher SBP, worse WFNS grades and ruptured MCA aneurysms were independently associated with ICH on admission.
- MeSH
- Cerebral Hemorrhage complications MeSH
- Stroke * complications MeSH
- Hematoma diagnostic imaging epidemiology etiology MeSH
- Intracranial Aneurysm * complications diagnostic imaging surgery MeSH
- Middle Aged MeSH
- Humans MeSH
- Prospective Studies MeSH
- Subarachnoid Hemorrhage * complications diagnostic imaging MeSH
- Treatment Outcome MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Multicenter Study MeSH
- Geographicals
- Vietnam MeSH
OBJECTIVES: To compare the accuracy of the Sequential Organ Failure Assessment (SOFA) and Acute Physiology and Chronic Health Evaluation II (APACHE II) Scores in predicting mortality among intensive care unit (ICU) patients with sepsis in a low-income and middle-income country. DESIGN: A multicentre, cross-sectional study. SETTING: A total of 15 adult ICUs throughout Vietnam. PARTICIPANTS: We included all patients aged ≥18 years who were admitted to ICUs for sepsis and who were still in ICUs from 00:00 to 23:59 of the specified study days (ie, 9 January, 3 April, 3 July and 9 October of the year 2019). PRIMARY AND SECONDARY OUTCOME MEASURES: The primary outcome was hospital all-cause mortality (hospital mortality). We also defined the secondary outcome as all-cause deaths in the ICU (ICU mortality). RESULTS: Of 252 patients, 40.1% died in hospitals, and 33.3% died in ICUs. SOFA Score (areas under the receiver operating characteristic curve (AUROC): 0.688 (95% CI 0.618 to 0.758); cut-off value≥7.5; PAUROC<0.001) and APACHE II Score (AUROC: 0.689 (95% CI 0.622 to 0.756); cut-off value ≥20.5; PAUROC<0.001) both had a poor discriminatory ability for predicting hospital mortality. However, the discriminatory ability for predicting ICU mortality of SOFA (AUROC: 0.713 (95% CI 0.643 to 0.783); cut-off value≥9.5; PAUROC<0.001) was fair and was better than that of APACHE II Score (AUROC: 0.672 (95% CI 0.603 to 0.742); cut-off value≥18.5; PAUROC<0.001). A SOFA Score≥8 (adjusted OR (AOR): 2.717; 95% CI 1.371 to 5.382) and an APACHE II Score≥21 (AOR: 2.668; 95% CI 1.338 to 5.321) were independently associated with an increased risk of hospital mortality. Additionally, a SOFA Score≥10 (AOR: 2.194; 95% CI 1.017 to 4.735) was an independent predictor of ICU mortality, in contrast to an APACHE II Score≥19, for which this role did not. CONCLUSIONS: In this study, SOFA and APACHE II Scores were worthwhile in predicting mortality among ICU patients with sepsis. However, due to better discrimination for predicting ICU mortality, the SOFA Score was preferable to the APACHE II Score in predicting mortality.Clinical trials registry - India: CTRI/2019/01/016898.
- MeSH
- Adult MeSH
- Intensive Care Units MeSH
- Humans MeSH
- Southeast Asian People MeSH
- Prognosis MeSH
- Cross-Sectional Studies MeSH
- Retrospective Studies MeSH
- ROC Curve MeSH
- Sepsis * MeSH
- Organ Dysfunction Scores * MeSH
- Check Tag
- Adult MeSH
- Humans MeSH
- Publication type
- Journal Article MeSH
- Multicenter Study MeSH
- Geographicals
- Vietnam MeSH
Histaminová intolerance (HIT) je neimunologická reakce organismu na požitý histamin. Projevy HIT zahrnují intestinální a negastrointestinální projevy. Klinické projevy HIT jsou nespecifické a mohou napodobovat alergické příznaky, potravinové intolerance, mastocytózu, syndrom aktivovaných mastocytů (MCAS) a další. Stanovení diagnózy HIT je komplikované. Nabízí se celá řada kandidátních testů, nicméně s nejasnou výpovědní hodnotou. V současnosti je pro stanovení diagnózy nejdůležitější pozitivní klinický efekt po zavedení nízkohistaminové diety. Rovněž základem léčby je v současnosti nízkohistaminová dieta. Další terapeutické možnosti, jako suplementace DAO, léčba antihistaminiky nebo probiotiky, jsou nyní považovány za doplňkovou léčbu. Článek shrnuje aktuální informace o etiologii, klinických projevech, aktuálních možnostech diagnostiky a léčby onemocnění.
Histamine intolerance (HIT) is a non-immunological disorder associated with an impaired ability to metabolize ingested histamine. Manifestation of HIT includes gastrointestinal and non-gastrointestinal symptoms. Clinical symptoms of HIT are non-specific and can imitate different diseases such as allergies, food intolerance, mastocytosis and other. The diagnosis of HIT is difficult. There are several candidate tests to detect DAO insufficiency, but their informative value is questionable. Currently, a positive clinical effect of a low-histamine diet is the most important for establishing the diagnosis. Equally in the treatment, a low-histamine diet is the most crucial approach. Other therapeutic options such as DAO supplementation treatment with antihistamines or probiotics are considered as complementary treatments. Our article provides a review on histamine intolerance, focusing on etiology and the diagnostic and treatment possibilities.
